Bruker Corp Stock Price, News & Analysis

Bruker (Nasdaq: BRKR) announced approximately $25 million of orders for high-performance magnetic resonance systems from three European research institutions, with revenue recognition expected over fiscal 2026 and 2027.

Orders include a novel NMR relaxometry system for École Normale Supérieure (ENS-PSL) to complement a 900 MHz spectrometer, two 800 MHz and one 100 MHz systems plus an E580 EPR spectrometer for Max Planck Institute for Solid-State Research focused on battery materials, and an ultra-high field 1 GHz NMR system for Institut Européen de Chimie et Biologie (IECB) as Bordeaux’s flagship platform. Separately, a second 1.2 GHz NMR system was accepted at the University of Birmingham in Q4 2025.

Bruker (Nasdaq: BRKR) said it has appointed diagnostics executive Jack J. Phillips to its board of directors, effective January 1, 2026. Mr. Phillips brings more than 30 years of leadership in diagnostics, including roles as President & CEO of Accelerate Diagnostics (2020–2025) and President & CEO of Roche Diagnostics North America (2010–2020).

Bruker highlighted Phillips' experience in rapid antibiotic susceptibility testing, clinical chemistry, immunodiagnostics, molecular and point-of-care diagnostics, and digital pathology, and said his expertise aligns with Bruker's focus on expanding its infectious disease diagnostics portfolio and leveraging disease-biology research tools for specialty diagnostics.

AST Revolution was announced as sold to Bruker (Nasdaq: BRKR, BRKRP) on November 24, 2025. Financial terms were not disclosed. AST Revolution launched in August 2025 after a court-approved acquisition of select assets of Accelerate Diagnostics under Chapter 11, and the deal includes the WAVE™ and Arc™ systems plus associated intellectual property. Indaba Capital, AST Revolution’s controlling sponsor, provided ongoing funding and operational support to rebuild the platform, advance product development, and position the business for this sale.

The company highlights continued scientific leadership under Chief Scientific Officer Lawrence Mertz and says Bruker is expected to be the long-term owner to commercialize the next-generation rapid antimicrobial susceptibility testing technologies.

Bruker (Nasdaq: BRKR, BRKRP) announced quarterly cash dividends for common and preferred shares.

The Board approved a $0.05 per share common stock dividend, payable January 2, 2026 to holders of record as of December 8, 2025. The Board also approved a $3.6745 per share dividend on the 6.375% Mandatory Convertible Preferred Stock, Series A, payable December 1, 2025 to holders of record as of November 15, 2025.

Bruker (Nasdaq: BRKR) will report third quarter 2025 financial results before market open on Monday, November 3, 2025.

The company will host a live conference call and webcast at 8:30 a.m. Eastern Time to discuss results and current business trends. A slide presentation will be posted to the investor website shortly before the webcast. Investors can access the webcast at https://ir.bruker.com or join by phone at 1-888-437-2685 (U.S.) or +1-412-317-6702 (international).

Pre-registration is available at https://dpregister.com/sreg/10204017/100302815b8 to receive a personalized dial-in and PIN. A telephone replay will be available beginning one hour after the call through December 3, 2025 at 1-877-344-7529 (U.S.) or +1-412-317-0088 using access code 6763149.

Bruker (Nasdaq: BRKR) announced three federally funded NMR system orders totaling approximately $10 million, placed by the New York Structural Biology Center, University of Delaware and Northwestern University on October 3, 2025. The NYSBC order is an NIH-funded 700 MHz Multifield NMR Relaxometry system—the first in North America—serving a 9-institution New York consortium and the national NIH center. Delaware ordered a NSF-funded 600 MHz DNP NMR to serve 25+ internal groups and 12 collaborators. Northwestern ordered an 800 MHz spectrometer supporting 15+ NIH-funded groups. Deliveries are expected in 2026.

Bruker Corporation (Nasdaq: BRKR) has announced the pricing of its public offering of $600 million of 6.375% Mandatory Convertible Preferred Stock, Series A. The offering includes 2.4 million shares at a liquidation preference of $250 per share, with a 30-day option for underwriters to purchase an additional $90 million.

The preferred stock will automatically convert to common stock on September 1, 2028, with conversion rates between 6.9534 and 8.5179 shares of common stock per preferred share. Dividends will be paid quarterly at a 6.375% annual rate starting December 1, 2025. The company expects net proceeds of approximately $582 million, which will be used to repay various term loans and credit facilities.

Bruker Corporation (Nasdaq: BRKR) has announced a public offering of $600 million in Mandatory Convertible Preferred Stock, Series A. The offering includes 2.4 million shares with a liquidation preference of $250 per share, with an additional 30-day option for underwriters to purchase up to $90 million more shares.

The company plans to use the proceeds to strengthen its balance sheet by repaying various loans, including a term loan due December 2026, outstanding borrowings under its 2024 revolving credit agreement, and part of a term loan due March 2027. The preferred stock will automatically convert to common stock around September 1, 2028, unless converted earlier by holders.